These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review. Fernández-Lázaro D; Iglesias-Lázaro M; Garrosa E; Rodríguez-García S; Jerves Donoso D; Gutiérrez-Abejón E; Jorge-Finnigan C Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837449 [TBL] [Abstract][Full Text] [Related]
64. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis. Schwier NC Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270 [TBL] [Abstract][Full Text] [Related]
65. Rilonacept for the treatment of recurrent pericarditis. Fava AM; Reyaldeen R; Lo Presti S; Goyal A; Akintoye E; Hughes D; Klein AL Expert Opin Biol Ther; 2022 Jan; 22(1):7-16. PubMed ID: 34757872 [TBL] [Abstract][Full Text] [Related]
66. Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis. Wang TKM; Klein AL Curr Cardiol Rep; 2022 Jan; 24(1):23-30. PubMed ID: 34993745 [TBL] [Abstract][Full Text] [Related]
67. The Role of Rilonacept in Recurrent Pericarditis. Presti SL; Elajami TK; Reyaldeen R; Anthony C; Klein AL Heart Int; 2021; 15(1):20-25. PubMed ID: 36277322 [TBL] [Abstract][Full Text] [Related]